Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 23 July 2021

This extraordinary meeting is organised in the context of the evaluation of an application to extend the use of Spikevax (previously COVID-19 Vaccine Moderna), a vaccine for COVID-19, to include children aged 12 to 18.

The aim of the meeting is to conclude the evaluation, if possible.

The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.